Showing results (31-40 of 431) with videos related to

Sort By:
Pageof 44
Thoracic Cancer|October 21, 2020
Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case seriesRyoko Inaba-Higashiyama, Tatsuya Yoshida, Hitomi Jo, et al.
Immunotherapy|September 27, 2019
Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilarMichael Thomas, Nick Thatcher, Jerome Goldschmidt, et al.
Lung Cancer (Amsterdam, Netherlands)|March 24, 2015
Immunohistochemical status of PD-L1 in thymoma and thymic carcinomaYuki Katsuya, Yu Fujita, Hidehito Horinouchi, et al.
Oncotargets and Therapy|May 7, 2021
Alectinib for Miliary Lung Metastasis in ALK-Positive Lung AdenocarcinomaHironori Satoh, Yusuke Okuma, Jumpei Kashima, et al.
Cancer Science|August 25, 2021
Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillanceNobuyuki Yamamoto, Yoichi Nakanishi, Akihiko Gemma, et al.
Anticancer Research|March 14, 2013
Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung diseaseTatsuya Yoshida, Kiyotaka Yoh, Koichi Goto, et al.
Japanese Journal of Clinical Oncology|March 19, 2019
Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathologyToshiyuki Nakai, Yuji Matsumoto, Shinji Sasada, et al.
Translational Lung Cancer Research|December 13, 2023
Identifying factors causing failure of nodal staging by endobronchial ultrasound-guided transbronchial needle aspiration in non-small cell lung cancerClara So, Yuji Matsumoto, Tatsuya Imabayashi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II studySeiji Niho, Yuichiro Ohe, Hironobu Ohmatsu, et al.
Cancer Science|June 29, 2007
Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicityIkuo Sekine, Kazuhiko Yamada, Hiroshi Nokihara, et al.
Pageof 44